治疗2型糖尿病药物——考格列汀  

A new drug for type 2 diabetes mellitus:cofrogliptin

作　　者：张娇娇 刘以安 方翼[1,2] ZHANG Jiaojiao;LIU Yian;FANG Yi(Clinical Trial Organization,People's Hospital of Peking University,Beijing 100044,China;School of Pharmacy,Xuzhou Medical University,Jiangsu Xuzhou 221004,China)

机构地区：[1]北京大学人民医院临床试验机构,北京100044 [2]徐州医科大学药学院,江苏徐州221004

出　　处：《临床药物治疗杂志》2025年第2期27-31,共5页Clinical Medication Journal

摘　　要：考格列汀是一种超长效二肽基肽酶Ⅳ(DPP-4)抑制剂,2024年6月18日经国家药品监督管理局批准上市。考格列汀具有半衰期长、对DPP-4抑制持久的特点,单药或与二甲双胍联合使用可显著改善成人2型糖尿病患者的血糖水平。为进一步加深临床工作者对考格列汀的认识与理解,本文对考格列汀的药理作用、药动学、临床疗效、安全性、用法用量、药物相互作用等进行综述,同时与其他相关药物进行比较,为临床用药提供参考。Cofrogliptin is an ultra-long-acting dipeptidyl peptidaseⅣ(DPP-4)inhibitor that was approved for market by the National Medical Products Administration on June 18,2024.Cofrogliptin is characterized by a long half-life and sustained inhibition of DPP-4.It can significantly improve blood glucose levels in adult patients with type 2 diabetes mellitus when used as monotherapy or in combination with metformin.To further enhance clinical practitioners'understanding of cofrogliptin,this article provides a comprehensive review of its pharmacological action,pharmacokinetics,clinical efficacy,safety,dosage and administration,and drug interactions,while also comparing it with other related medications to provide references for clinical medication.

关 键 词：考格列汀 2型糖尿病 二肽基肽酶Ⅳ抑制剂 

分 类 号：R977.15[医药卫生—药品]